Comparing Management of Hypertension versus Atrial Fibrillation in CLL

Opinion
Video

Doctors discuss that while cardiovascular side effects like atrial fibrillation and hypertension in patients with chronic lymphocytic leukemia are concerns with BTK inhibitors, they are manageable and should not deter prescribing these effective therapies; generally, atrial fibrillation is considered more challenging to manage than hypertension.

Recent Videos
Although a greater risk of CNS relapse may emerge with immunotherapy-based backbones, toxicities associated with chemotherapy are avoided.
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
4 experts in this video
Related Content
Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.

Zanubrutinib Therapies Yield Durable Results in High-Risk, Treatment-Naïve CLL/SLL

ONCOLOGY Staff
December 23rd 2025
Article

Results from arms C and D of the phase 3 SEQUOIA trial demonstrated that zanubrutinib alone or in combination with venetoclax yields positive results in CLL/SLL subpopulations.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

CART19 Yields Promising Efficacy in CNS-Relapsed B-ALL

CART19 Yields Promising Efficacy in CNS-Relapsed B-ALL

Ariana Pelosci
December 16th 2025
Article

The 1-year EFS with CART19 was 90% among patients with B-ALL who had 1 or more CNS relapses.

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Charting the Evolution of TKIs and Finding the Next Breakthrough in CML

Jorge E. Cortes, MD
October 13th 2025
Podcast

Jorge Cortes, MD, outlines the impact of imatinib in chronic myeloid leukemia and highlights future initiatives in the field.

Data from the SEQUOIA trial support the use of zanubrutinib/venetoclax in CLL or SLL regardless of del(17p)/TP53 mutation or IGHV mutational status.

Zanubrutinib Regimen Sustains PFS Benefit Across CLL/SLL Mutation Statuses

Tony Berberabe, MPH
December 9th 2025
Article

Data from the SEQUOIA trial support the use of zanubrutinib/venetoclax in CLL or SLL regardless of del(17p)/TP53 mutation or IGHV mutational status.

Data from the BRUIN-CLL-313 study may support pirtobrutinib as a new potential standard of care for those with untreated CLL or SLL.

Pirtobrutinib Improves PFS in Treatment-Naive CLL/SLL

Sabrina Serani
December 9th 2025
Article

Data from the BRUIN-CLL-313 study may support pirtobrutinib as a new potential standard of care for those with untreated CLL or SLL.